Acasti Pharma 8-K: Executive Comp & Leadership Changes
Ticker: GRCE · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Acasti Pharma INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $290,000, $2.125 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, governance
TL;DR
**Acasti Pharma just filed an 8-K about executive changes; watch for impact on strategy and stock.**
AI Summary
Acasti Pharma Inc. filed an 8-K on January 5, 2024, to report changes in its executive compensation arrangements and potentially the departure or election of directors or officers. This filing is important for investors because changes in executive compensation or leadership can signal shifts in company strategy, financial health, or governance, which could impact the stock's future performance and investor confidence.
Why It Matters
Changes in executive compensation or leadership can signal strategic shifts or financial health concerns, directly influencing investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive compensation and leadership can introduce uncertainty regarding future company direction and stability, posing a medium risk to investors.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and compensation arrangements to assess their potential impact on Acasti Pharma's strategic direction and financial health.
Key Players & Entities
- Acasti Pharma Inc. (company) — the registrant filing the 8-K
- January 05, 2024 (date) — date of earliest event reported
- 001-35776 (other) — Commission File Number
- ACST (other) — Trading Symbol on The Nasdaq Stock Market LLC
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 05, 2024.
What specific items are covered in this 8-K filing by Acasti Pharma Inc.?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is Acasti Pharma Inc.'s trading symbol and on which exchange is it registered?
Acasti Pharma Inc.'s trading symbol is ACST, and its common shares are registered on The Nasdaq Stock Market LLC.
What is the business address of Acasti Pharma Inc. as stated in the filing?
The business address of Acasti Pharma Inc. is 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.
What is the Central Index Key (CIK) for Acasti Pharma Inc.?
The Central Index Key (CIK) for Acasti Pharma Inc. is 0001444192.
Filing Stats: 887 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-01-08 07:30:07
Key Financial Figures
- $290,000 — is entitled to an annual base salary of $290,000 and has a target bonus opportunity of u
- $2.125 — of the Company at an exercise price of $2.125 per share, which options vest in equal
Filing Documents
- acst-20240105.htm (8-K) — 43KB
- acst-ex10_1.htm (EX-10.1) — 21KB
- img95305537_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-002689.txt ( ) — 200KB
- acst-20240105_lab.xml (EX-101.LAB) — 13KB
- acst-20240105_pre.xml (EX-101.PRE) — 10KB
- acst-20240105.xsd (EX-101.SCH) — 2KB
- acst-20240105_htm.xml (XML) — 5KB
01 Exhibits
Item 9.01 Exhibits. (d) Exhibits Exhibit Description 10.1 Offer Letter by and between Robert J. DelAversano and the Company, dated November 21, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ACASTI PHARMA INC. Date: January 8, 2024 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer